Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Kidney cancer at ASCO GU 2025: CheckMate 9ER & LITESPARK-011

Eric Jonasch • 15 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer Antibodies Belzutifan Cabozantinib Checkpoint Inhibitors Nivolumab
CheckMate 9ER LITESPARK-011

Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides his highlights from the 2025 ASCO GU Cancers Symposium, including findings from the Phase III CheckMate 9ER trial (NCT03141177), which demonstrated promising results in first-line nivolumab plus cabozantinib. Additional trials of interest include the LITESPARK-011 trial (NCT05239728) of belzutifan combinations. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eric Jonasch

Evaluating the evolving role of belzutifan in renal cell carcinoma
1:13
Evaluating the evolving role of belzutifan in renal cell carcinoma
Eric Jonasch • 1 Jun 2025
STARLITE-1: 177Lu-Girentuximab, cabozantinib & nivolumab in ccRCC
0:54
STARLITE-1: 177Lu-Girentuximab, cabozantinib & nivolumab in ccRCC
Eric Jonasch • 1 Jun 2025
5-year follow-up results from LITESPARK-004
0:54
5-year follow-up results from LITESPARK-004
Eric Jonasch • 1 Jun 2025
Kidney cancer highlights from ASCO 2025
0:43
Kidney cancer highlights from ASCO 2025
Eric Jonasch • 1 Jun 2025

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals